Plant Advanced Technologies SA (FR:ALPAT)
:ALPAT
Top Page
Plant Advanced Technologies SA
(ALPAT)
Select Model
Select Model
Rating:60Neutral
Price Target:
€9.00
▲(9.49% Upside)
Action:ReiteratedDate:02/03/26
The score is primarily supported by improved 2024 financial performance (profitability, cash generation, and lower leverage). It is held back by mixed technicals (below the 200-day average and slightly negative MACD) and weak/unclear valuation signals due to a negative P/E and no dividend yield.
Positive Factors
Return to Profitability
A return to material profitability and a ~48% net margin in 2024 indicates the business can generate economic profit at current scale. Durable profits improve reinvestment capacity for R&D/commercialization, support creditor confidence, and reduce reliance on dilutive financing if maintained.
Negative Factors
Small, Volatile Revenue Base
A small and volatile revenue base undermines the durability of margins and cash flow; sharp swings (deep declines in prior years and a modest rebound) increase execution risk, limit scale economies, and make multi-quarter forecasting and reinvestment planning more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to Profitability
A return to material profitability and a ~48% net margin in 2024 indicates the business can generate economic profit at current scale. Durable profits improve reinvestment capacity for R&D/commercialization, support creditor confidence, and reduce reliance on dilutive financing if maintained.
Read all positive factors
Plant Advanced Technologies SA (ALPAT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€8.80M
Dividend YieldN/A
Average Volume (3M)388.00
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,132,326
10 Day Avg. Volume379
30 Day Avg. Volume388
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.44
Price to Sales (P/S)6.86
P/FCF Ratio6.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Plant Advanced Technologies SA Business Overview & Revenue Model
Company Description
Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include PAT Plant Milking that produces active extracts through plant stim...
How the Company Makes Money
null...
Plant Advanced Technologies SA Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
64
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.34M | 1.93M | 1.68M | 2.34M | 2.31M | 1.72M |
| Gross Profit | -4.65M | 2.24M | 2.15M | -4.65M | -2.73M | -2.82M |
| EBITDA | -744.00K | 956.45K | 72.53K | -744.00K | -1.27M | -819.00K |
| Net Income | -849.00K | 935.13K | 79.17K | -849.00K | -1.13M | -543.00K |
Balance Sheet | ||||||
| Total Assets | 17.08M | 16.00M | 14.91M | 17.08M | 17.11M | 17.27M |
| Cash, Cash Equivalents and Short-Term Investments | 669.00K | 79.70K | 0.00 | 669.00K | 2.49M | 3.26M |
| Total Debt | 5.97M | 3.42M | 4.36M | 5.97M | 6.14M | 5.73M |
| Total Liabilities | 10.29M | 6.83M | 6.78M | 10.29M | 9.73M | 8.73M |
| Stockholders Equity | 5.50M | 9.17M | 8.13M | 5.50M | 6.36M | 7.53M |
Cash Flow | ||||||
| Free Cash Flow | -1.20M | 2.08M | 972.53K | -479.00 | -504.00 | -499.00 |
| Operating Cash Flow | -449.82K | 2.50M | 1.85M | -274.00 | -388.00 | 78.00 |
| Investing Cash Flow | -724.25K | -1.59M | -1.28M | -1.97K | -1.11K | -1.18K |
| Financing Cash Flow | 107.14K | -585.89K | -851.03K | 244.00 | 743.00 | 2.38K |
Plant Advanced Technologies SA Peers Comparison
UnderperformOutperform
Sector (51)
FR:ALPAT
Plant Advanced Technologies SA
7.80
-2.59
-24.93%
DE:3HB
Hybrigenics SA Class A
―
―
―
DE:0N6A
TME Pharma N.V.
0.07
<0.01
4.76%
DE:8JD
Valbiotis SA
1.03
0.04
3.95%
DE:3VG
Theranexus SA
3.01
2.65
734.72%
DE:82F
NFL Biosciences SA
0.96
-0.41
-29.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.